Comparison
Oxytocin vs. Teduglutid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
50-56-6
197922-42-2
Molecular weight
1007.19 g/mol
3752.13 g/mol
Half-life
0.05 h
no data
Sequence
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2no data
Mechanism of action
Oxytocin
Oxytocin is synthesised in the hypothalamus and released via the posterior pituitary. Peripherally it binds the oxytocin receptor, a G-protein-coupled receptor, and through the phospholipase-C cascade and calcium release triggers contraction of uterine smooth muscle and milk ejection — the pharmacological basis of the obstetric approval. Centrally, oxytocin acts as a neuromodulator and has been linked to social bonding, trust and modulation of stress and anxiety circuits. Its central effects in humans are mechanistically incompletely understood, particularly because it is unclear to what extent peripherally or intranasally administered oxytocin crosses the blood-brain barrier.
Teduglutid
Teduglutide activates the GLP-2 receptor, promoting growth and regeneration of small-intestinal villi, increasing nutrient and fluid absorption and thereby reducing dependence on parenteral nutrition. The glycine substitution at position 2 makes it resistant to rapid breakdown by DPP-4.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
2
of which in humans
4
2
Effects recorded
3
2
Open conflicts
1
0
Documented adverse events
0
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Oxytocin and Teduglutid?
- Oxytocin is classified as "Research other", while Teduglutid is classified as "Research other". Oxytocin: Oxytocin is an endogenous nonapeptide hormone of the posterior pituitary. In synthetic form (Pitocin, Syntocinon) it has been approved for decades to induce and augment labour and to control postpartum uterine bleeding. Strictly separate from this is intranasal use to influence social behaviour, trust, anxiety or autism symptoms: this use is unapproved, purely experimental, and yields inconsistent and often negative results in controlled trials. Teduglutid: Teduglutide is a DPP-4-resistant analog of GLP-2 (glucagon-like peptide-2). It promotes growth and function of the intestinal mucosa and is approved for treating short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Oxytocin or Teduglutid?
- The highest available evidence level is "Human RCT" for Oxytocin and "Human RCT" for Teduglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Oxytocin and Teduglutid in Germany and the United States?
- Germany: Oxytocin — Prescription, Teduglutid — Prescription. United States: Oxytocin — Prescription, Teduglutid — Prescription. These are factual summaries with source and review date on the individual pages.